Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab vs Chemotherapy in dMMR Advanced or Recurrent Endometrial Carcinoma
NCT05173987Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2022
- Primary completion
- May 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 27
01
Overview
A Phase 3 trial of pembrolizumab in endometrial carcinoma, sponsored by Merck & Co.. Started Feb 2022; status: active, not recruiting.
02
Drugs
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT05173987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05173987.